Pharmaceutical

STAT+: RNA startup ReNAgade cuts staff seven months aft...

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after r...

ChatGPT doesn’t know much about drugs, Hims & Hers ente...

In the latest edition of STAT's health tech newsletter: ChatGPT doesn't know muc...

STAT Morning Rounds: The health news you need to read t...

Understand how science, health policy, and medicine shape the world everyday. Si...

Carmot’s chance of beating the odds in the biotech mark...

Want to stay on top of the science and politics driving biotech today? Sign up t...

Aficamten by Cytokinetics for Diastolic Heart Failure (...

Aficamten is under clinical development by Cytokinetics and currently in Phase I...

TTI-101 by Tvardi Therapeutics for Head And Neck Squamo...

TTI-101 is under clinical development by Tvardi Therapeutics and currently in Ph...

Ketamine ER by Douglas Pharmaceuticals for Major Depres...

Ketamine ER is under clinical development by Douglas Pharmaceuticals and current...

SIM-325 by TCR Cure Biopharma Technology for Head And N...

SIM-325 is under clinical development by TCR Cure Biopharma Technology and curre...

Latozinemab by Alector for Frontotemporal Dementia (FTD...

Latozinemab is under clinical development by Alector and currently in Phase III ...

SGN-1 by Guangzhou Sinogen Pharmaceutical for Head And ...

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and curr...

RiMO-301 by Rimo Therapeutics for Recurrent Head And Ne...

RiMO-301 is under clinical development by Rimo Therapeutics and currently in Pha...

AZ-3102 by Azafaros for Niemann-Pick Disease Type C: Li...

AZ-3102 is under clinical development by Azafaros and currently in Phase II for ...

J-2H1702 by J2H Biotech for Metabolic Dysfunction-Assoc...

J-2H1702 is under clinical development by J2H Biotech and currently in Phase II ...

NN-9440 by Inversago Pharma for Metabolic Syndrome: Lik...

NN-9440 is under clinical development by Inversago Pharma and currently in Phase...

Opinion: STAT readers on burnt-out infectious disease d...

Letters to the editor: “It's no wonder that ID doctors are some of the most burn...

STAT+: Takeda, Janssen join wearable maker to measure s...

In the latest edition of Health Tech newsletter: Takeda, Janssen team up with Ac...